Recombinant Human Synaptophysin-like protein 1 (SYPL1)

What is Human Synaptophysin-like protein 1 (SYPL1) and what are its basic characteristics?

SYPL1, also known as H-SP1 or SYPL, is a protein-coding gene (Entrez Gene ID: 6856) in humans that belongs to the synaptophysin family . It functions as a neuroendocrine-related protein with structural similarities to synaptophysin . The protein plays important roles in cellular processes including cell proliferation and survival pathways.

Key characteristics include:

How should researchers design experiments to investigate SYPL1 function in cellular models?

When designing experiments to investigate SYPL1 function, researchers should follow a systematic approach:

• Begin with a specific research question (e.g., "How does SYPL1 affect cell proliferation in pancreatic cancer cells?")

• Define your variables clearly:

  • Independent variable: SYPL1 expression levels

  • Dependent variable: Cellular phenotype (proliferation, apoptosis, etc.)

  • Control for extraneous variables (cell culture conditions, passage number, etc.)

A foundational experimental design should include:

• Comparison of multiple cell lines with varying baseline SYPL1 expression

• Both gain-of-function and loss-of-function experiments

• Appropriate controls (empty vector, scrambled siRNA/shRNA)

• Multiple methods to measure the same outcome (e.g., CCK8 assay and colony formation for proliferation)

For example, researchers studying SYPL1 in PDAC successfully employed both lentiviral-mediated knockdown and overexpression models in BxPC-3 and PANC-1 cell lines, cultured at 37°C in 5% CO₂ with 10% fetal bovine serum supplementation .

What are recommended cell lines and culture conditions for studying recombinant SYPL1?

Based on published research, the following experimental systems have proven effective:

These cell lines have been successfully used to study SYPL1 function in the context of pancreatic cancer research .

What is the role of SYPL1 in pancreatic ductal adenocarcinoma (PDAC) pathogenesis?

SYPL1 appears to play a significant role in PDAC pathogenesis based on multiple lines of evidence:

How can researchers effectively manipulate SYPL1 expression in experimental models?

Based on published methodologies, researchers can effectively manipulate SYPL1 expression using several approaches:

For SYPL1 Knockdown:

• Lentiviral shRNA: Stable knockdown can be achieved using lentiviral vectors carrying shRNA targeting SYPL1. The validated target sequence "CCTCATAGGCGATTACTCT" has been successfully used in PDAC cell lines .

• siRNA Transfection: Transient knockdown can be achieved using siRNA transfected with Lipofectamine 2000 following manufacturer's protocols .

For SYPL1 Overexpression:

• Lentiviral Expression System: Stable overexpression can be established using lentiviral vectors carrying the SYPL1 coding sequence .

Verification of Manipulation:

Researchers should verify successful manipulation through:

• Western blot analysis of protein expression

• qRT-PCR for mRNA expression changes

• Functional assays (proliferation, apoptosis, etc.) to confirm phenotypic changes

How should researchers design experiments to study SYPL1's role in apoptosis regulation?

To effectively investigate SYPL1's role in apoptosis regulation, researchers should employ a comprehensive experimental design:

• Manipulation of SYPL1 Expression:

  • Use both knockdown (shRNA, siRNA) and overexpression systems

  • Include appropriate controls (scrambled shRNA, empty vector)

  • Verify expression changes by Western blot and qRT-PCR

• Apoptosis Detection Methods (use at least two independent methods):

  • Flow cytometry with Annexin V/PI staining

  • TUNEL assay

  • Western blot analysis of apoptotic markers (cleaved caspase-3, cleaved PARP)

  • Mitochondrial membrane potential assessment

• Mechanistic Investigation:

  • Measure ROS levels (e.g., using DCFH-DA probe)

  • Assess ERK activation status by Western blot (phospho-ERK vs. total ERK)

  • Use ROS scavengers (e.g., N-acetylcysteine) to determine if ROS mediates SYPL1's effects

  • Use ERK pathway inhibitors to assess pathway dependence

• Timeline Considerations:

  • Include both early (6-24h) and late (24-72h) time points

  • Monitor pathway activation kinetics

This experimental framework will allow for comprehensive assessment of how SYPL1 regulates apoptosis and the intermediary pathways involved .

How can multi-omics data integration approaches be applied to SYPL1 research?

Vertical data integration methods can significantly enhance SYPL1 research by combining gene expression data with regulatory information:

• Integration Approaches:

  • Decomposition-Integration Approach: This method explicitly exploits the regulation relationship and can effectively eliminate correlation. For example, the LRM-SVD approach considers the regulation model X=ηZ+E, where estimation is achieved using Lasso followed by sparse SVD (singular value decomposition) .

• Application to SYPL1 Research:

  • Integrate SYPL1 expression data with:

    • DNA methylation profiles

    • miRNA expression data

    • Mutation data

    • Proteomic data

    • Metabolomic data

• Clustering Analysis:

  • Methods like Clusternomics/BayesianCC, iCluster, and SNF can identify molecular subtypes based on integrated data .

  • For example, analyzing SYPL1 expression alongside other molecular features in PDAC samples could reveal distinct patient subgroups with different clinical outcomes.

• Analysis Workflow:

  • Generate a correlation network between SYPL1 and potential regulators

  • Apply dimensionality reduction techniques

  • Identify key nodes and pathways connected to SYPL1

  • Validate findings through experimental approaches

This approach has been successfully applied in studies analyzing TCGA and PACA-AU datasets, where SYPL1's association with tumor characteristics and patient outcomes was established .

What are the best practices for analyzing contradictory data regarding SYPL1 expression across different cancer types?

When encountering contradictory data regarding SYPL1 expression or function across different cancer types or studies, researchers should follow these best practices:

• Systematic Data Collection and Comparison:

  • Create a comprehensive table of SYPL1 expression patterns across multiple cancer types

  • Note the specific methodologies used in each study (IHC, RNA-seq, microarray)

  • Consider sample sizes and statistical power of each study

• Context-Specific Analysis:

  • Recognize that SYPL1 may have context-dependent functions in different tissues

  • Consider tissue-specific binding partners or post-translational modifications

  • Analyze cell type-specific effects (e.g., epithelial vs. stromal expression)

• Technical Validation:

  • Verify antibody specificity for SYPL1 detection

  • Cross-validate findings using multiple methodologies

  • Consider isoform-specific expression patterns

• Functional Validation:

  • Design experiments to test SYPL1 function in multiple cell types

  • Use in vivo models representative of different cancer types

  • Consider patient-derived xenografts to maintain tumor heterogeneity

• Mechanistic Resolution:

  • Investigate whether contradictory findings reflect differences in:

    • Underlying genetic background

    • Tumor microenvironment

    • Disease stage

    • Therapeutic interventions

This structured approach helps researchers reconcile apparently contradictory data and may reveal nuanced biological insights about SYPL1's role in cancer biology.